

TABLE OF CONTENTS

April 21, 2008

No. 2087

BUSINESS

- 1 Takeda to Acquire Millennium for US\$8.8 Billion
- Aiming at Enhancing Its Presence in Oncology
- New Products for IBD, Inflammation Also in Pipeline
- To Become One of the Top-Three Companies in Oncology
- 4 Shionogi to Have Own Marketing Forces in US
- Acquisition Is Also an Option: Dr Teshirogi
- Building Up a 1,500-MR System in Japan
- 5 Diovan Back to No. 1 Position in February: Rep Track Survey
- 6 JHSF Proposes Support of Alliances
- 6 Global Market for Drugs for Alzheimer's Disease to Expand to US\$9.2 Bil.: Datamonitor
- 6 **BUSINESS NEWS IN BRIEF**
- Mohrus Tape L Drives Hisamitsu's Sales, Profits
- Akiyama Jozai Creates Contract Manufacturing Firm Specializing in High-Activity Drugs
- 7 **Commentary**
- Personnel Strategy - New Graduates or Work-Ready MRs?

GENERICIS

- 8 Orchid of India Announces Entry into Japanese Market
- We Will Succeed Where Global Pharmas Have Failed: Dr C.B. Rao
- 9 Generic Makers to Embark on Mergers, Tie-ups: Mr Sawai
- 9 Drug Cost Cut by 6% by Generic Substitution in 1st Week of April: Nihon Chouzai
- 9 No More Than 10% of Prescriptions Will Be Substituted with Generics: Dr Muto
- 10 Doctors Should Collect Information Themselves when Using Generics: Prof. Ogata
- 10 *Koroshō* to Punish Healthcare Providers Who Don't Try to Use More Generics: Mr Nakagaki
- Generics Used Only if Their Use Does Not Impair Quality of Healthcare: Kameda Medical Center
- Generic Makers Should Stop Free Ride
- 11 New Prescription Form Is Working Well: Mr Takeda

REGULATORY

- 12 PMDA Should Support R&D from Patients' Viewpoints: New PMDA Chief Executive
- 12 **TOPICS**
- Q&A Issued on GL on Drugs Using Autologous Cells
- 13 LDP Begins Discussions on the Need for a Japanese Version of FDA
- 13 LDP Proposes Creation of a Japanese Version of FDA

R&D

- 14 Eisai Discontinues Development of E2007 for Parkinson's Disease
- 14 Closure of Labs in Japan Consequence of a Natural Course of Events: Dr Kobayashi of PhRMA

- 15 Council Selects iPS Cells as Priority Technology
- Five of 16 Papers on iPS Cells Published by Prof. Yamanaka's Group
- 15 JSRM Calls For Deregulations over Research Using Human ES Cells
- 16 **Commentary**
- Industry-Academia Cooperation Essential for Practical Use of iPS Cells
- 17 JPMA Calls For Creation of Clinical Trials Centers
- 17 **R&D NEWS IN BRIEF**
- MediciNova Obtains Good Results with MN-166 for Multiple Sclerosis
- UMN Pharma to Start PI/II Study of Vaccine for New-Type Flu
- Nano Carrier Obtains Exclusive License on Micelles for Nucleic Acid from TOUDAI TLC
- Kringle Pharma Patents NK4 in Japan
- AnGes MG's Topical Formulations of NF-κB Decoy Oligo Patented in Europe
- Takeda Considers Application for Additional Indication for Actos in the US
- Actos Prevents Progression of Atherosclerosis Assessed by IVUS: Takeda
- Prasugrel Cuts ST Risk in Patients Undergoing PCI: Daiichi Sankyo
- Regression of Atherosclerosis by Crestor Demonstrated by QCA: AZ
- Levitra Effective for Men with Hypercholesterolemia: Bayer
- Livalo and Lipitor Reduce Coronary Arterial Plaque

SELF-MEDICATION

- 20 Opinions Split on Whether Only Pharmacists Should Be Allowed to Manage Stores
- Tests for "Registered Drug Salesperson" Should Be Held at Least Twice a Year: JACDS

NEWPRODUCTS

- 20 - Rohto: Switch OTC Drug for Recurrent Vaginal Candidiasis

OPINION

- 21 - How to Get Lucky in Your Pharma Career: Philip Carrigan

MEDICAL FACILITIES & NURSING CARE

- 22 NCC to Take Full Advantage of New System to Provide Advanced Healthcare to More Patients
- 22 Further Spread of Hepatitis C Viral Infections Unlikely: Chugai Seminar

MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF

- 23 - JAOG Calls For Early Approval of Uterocervical Cancer Vaccines
- Profitability of Vaccines Remains Low: Makers' Association
- Body's "Turning Point" Reached at 32 Years of Age: Novo Nordisk Survey